Kornimate/medical-research-clean huggingface dataset:
critical treatment of coronary artery disease

Conditions: Coronary Artery Disease; Coronary Artery Disease Progression

Summary: identifying the critical lesion of coronary artery disease and determining the interventional plan are significant for reducing adverse cardiovascular adverse events. the assessment of critical lesion requires the consideration of plaque morphology, tissue composition, and endometrial stress which leading to rupture. in summary, accurate assessment of critical lesions has high application value. in this study, patients with critical coronary artery disease were divided into two groups: an accurate assessment group and a simple assessment group, with the aim to compare the diagnosis and treatment efficiency as well as prognosis, potential cardiovascular risk, possible "excessive" intervention.


Eligibility criteria:
inclusion criteria: volunteered to participate in this study and signed an informed consent form; men or non-pregnant women ≥ 18 and ≤80 years of age; lesion is located in a coronary artery and stenosis is between 50-75%; exclusion criteria: severe liver and kidney diseases (gfr\<60 ml/min/1.73m2 or ctp≥6 score); moderate to severe hypertension (after standard antihypertensive therapy, blood pressure higher than 160/100mmhg); patients with hemodynamic or electrical instability (including shock); coagulation disorders associated with significant bleeding tendency (eg, hypersensitivity, active bleeding, moderate or severe liver disease, gi bleed within the past 6 months, major surgery within 30 days); patients with ischemic stroke within one week; any contraindication against the use of anti-platelet drugs such as aspirin; platelet count less than 100 x 109/l, haemoglobin (hb) level less than 100 g/l; researchers involved in the study and / or immediate family members; participation in another investigation drug or device study in the past 30 days before enrollment; involvement in the planning and conduct of the study (applies to staffs at study sites); suffering from serious arrhythmias include recurrent ventricular tachycardia or ventricular fibrillation; pregnancy or lactation or females of child-bearing potential with the plan of pregnancy in one year;

Keywords: coronary artery disease critical lesion
predictors of malnutrition in patients with haematological cancer

Conditions: Malnutrition; Lymphoma

Summary: the primary purpose of this study is to conduct an exploratory study of which predictors are most significant for lbm loss in patients with lymphoma. patients are measured by weight and bio impedance and furthermore, their physical activity, nutritional status, diet and quality of life during the course are estimated. this is done in order to determine any changes in the aforementioned factors during the course of the cancer treatment that may have a bearing on the loss of lbm.

it was assessed by the national ethics committee that the experiment was not subject to notification, cf. section 14 (1) of the committee act. 2. the project has been approved by the ethical research committee for sund and science, university of copenhagen.. the project was also approved by the danish data protection agency at region zealand with case no .: reg-166-2020. a data processor agreement was established between region zealand and thesis students. data is presented as mean +/- sd. continuous data are analyzed using pearson correlation analysis presented by correlation coefficient r and a p-value. pearson correlation analysis is used to measure the strength of the linear relationship between normally distributed variables. a significance level of 5% is used. binary values are assigned for data assessing secondary endpoints. subsequently, a multiple linear regression analysis is performed to examine the influence of discrete variables on the primary endpoint. for statistical analysis and design of plots, the programs, r studio (version 1.4.1106) and excel (version 16.43) is used.

Eligibility criteria:
inclusion criteria: * patients with haematological cancer * patients receiving myelosuppressive chemotherapy for haematological disease * adult patients exclusion criteria: * patients who cannot understand and speak danish or english * pregnant and breastfeeding * patients who suffer from dementia
real-world experiences of alcohol and cognitions over time

Conditions: Alcohol Intoxication

Summary: the goal of this clinical trial is to examine how alcohol affects young adults' attention in both laboratory and real-world settings through phone-based cognitive tasks. the main questions this trial is designed to answer are: * how well do the phone-based cognitive tasks capture alcohol's effects on attention? * does the effect of alcohol on attention contribute to risk-taking? participants will complete cognitive tasks to assess attention before and after consuming a standard amount of alcohol in the laboratory, and during surveys completed through a phone app for eight weekends.

the goal of this study is to develop cognitive tasks that assess alcohol-related attentional narrowing (i.e., alcohol myopia) for smartphone-based ecological momentary assessment (ema). in phase i, tasks were adapted from computer to smartphone format and refined through interviews with young adults who provided feedback on mock-ups. in phase ii (the current trial), feasibility, acceptability, reliability, and validity of the adapted tasks will be tested in lab and ema. young adults who pass an online pre-screening and phone screening will complete an initial lab session involving self-report questionnaires, alcohol consumption (target breath alcohol concentration \[brac\] = .08%), and general cognitive and myopia-specific tasks. all participants in phase ii will be assigned to receive a dose of alcohol in the lab session; task performance will be compared within individuals from before to after they are intoxicated. participants will remain in the lab until their brac reduces to a level of .03% and they can pass a field sobriety test. these same participants will then complete ema while wearing transdermal alcohol biosensors for 8 consecutive weekends, including one morning survey and at least two evening surveys per day. then, participants will return to the lab for a follow-up session involving self-report questions and an interview eliciting additional feedback. findings will help to clarify the role of alcohol myopia as a mechanism linking intoxication to real-world risk behaviors.

Eligibility criteria:
inclusion criteria: * aged 21-25 * drink at least 2x/week in the past month * at least 1 past-month heavy episodic drinking event (4+/5+ standard drinks in a day for females/males) * have an iphone * able to read and understand english * willing to complete all study procedures exclusion criteria: * history of alcohol-related treatment or hospitalization * medical contraindications for alcohol consumption (e.g., contraindicated medication, major psychiatric illness, history of seizure, gastric bypass surgery, cardiac pacemaker, major illness such as liver cirrhosis or hepatitis, past traumatic brain injury, asthma exacerbated by alcohol use, consistent flushing response to alcohol use) or pregnancy, nursing an infant, or plans to become pregnant in the next 8 weeks (i.e., during the ema monitoring period) * substantial visual impairment or color blindness (given that cognitive tasks rely on visual cues)
single-dose novel selective alpha2c antagonist pharmaco-mri study in healthy volunteers

Conditions: Healthy Volunteer

Summary: the aim of the present study is to investigate changes in neural activity (bold signal), as measured using fmri, in brain areas associated with emotional and working memory during task performance after single-dose administration of a novel selective alpha2c adrenoceptor antagonist (orm-12741) in healthy volunteers. further, it will be explored whether orm-12741 affects connectivity between brain areas in rest, as measured using fmri, and cognitive performance in the sample under investigation.


Eligibility criteria:
inclusion criteria: * good command of english language * right handedness * normal or corrected-to-normal vision exclusion criteria: * personal history or active presence of psychiatric conditions * usage of psychotropic medication within the past 3 months * pregnancy or breast-feeding status * systolic blood pressure \ 140 mmhg at screening visit * diastolic blood pressure \ 90 mmhg at screening visit * resting heart rate \ 100 beats/minute at screening visit * active presence of medical condition at physical examination * history of major traumatic brain injury * any other contraindication to mri of the brain * use of psychoactive substances incl. alcohol in 24 hours prior to test session

Keywords: noradrenalin agents physiological effects of drugs mood disorders behavioral symptoms
individual nutrition support in hbv-aclf patients at nutrition risk

Conditions: Malnutrition; Hepatitis B,Chronic; Acute-On-Chronic Liver Failure; Nutrition Support

Summary: this study aims to investigate the safety and efficacy of individual nutrition support for treating hepatitis b virus(hbv) related acute-on-chronic liver failure patients at nutrition risk

the aims of the randomized-controlled trial are to test the hypothesis that in medical inpatients with hbv related aclf at risk for undernutrition defined by the nutritional risk score (nrs 2002), tailored nutritional therapy to reach nutritional targets based on individualized nutritional counseling is a effective strategy to prevent mortality, morbidity and functional decline. sixty patients with hbv related aclf will be enrolled in this study. the participants are divided into trial patients in the trail group will receive individualized nutritional therapy to reach nutritional targets (caloric, protein, others) based on a predefined nutritional strategy.in control patients, according to patients' appetite, standard hospital nutrition will be served. nutritional therapy may be started in control patients, if any sort of swallowing disorders develops or if patients need to be prepared for operation. all patients will be re-assessed daily during the hospital stay for nutritional intake and nutritional therapy may be escalated within first 3days ( oral supplements, parenteral nutrition) if targets are not met (at least 75% of targets).

Eligibility criteria:
inclusion criteria: 1. age from 20 to 60 years old; 2. clinical diagnosis of chronic hepatitis b virus infection(positive hepatitis b surface antigen or positive hepatitis b virus dna \>0.5 year 3. serum total bilirubin level ≥12 mg/dl 4. prothrombin time international ratio ≥1.5 5. nrs≥ 3points 6. cossh-aclf iis \<8.4 points exclusion criteria: 1. other active liver disease; 2. hepatocellular carcinoma or other malignancy, hiv, chronic kidney disease(ckd), diabetes, thyroid disease, cardiopulmonary disease, neuromuscular diseases, serious psychiatric disease; 3. acute cholecystitis, acute pancreatitis, biliary obstruction, short bowel syndrome, intestinal obstruction, inflammatory bowel disease; 4. severe complications or other organ failure including sever infection, gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal failure(agi iii-iv); 5. pregnancy, bmi\<18.5 or bmi ≥28，organ transplantation, bed-ridden; 6. unable to ingest oral nutrition, contraindication against parenteral nutrition 7. admitted with enteral or parenteral nutrition in the last week 8. expected hospital length of stay\<3 days，.expected residence in guangdong province length of live\< 90 days
clinical and radiographic outcomes after amic treatment for talus osteochondral lesion trattamento artroscopico delle lesioni osteocondrali dell'astragalo con tecnica amic

Conditions: Talar Osteochondral Defect of Ankle; Pain; Arthroscopy

Summary: aim of the study is to evaluate clinical and radiographic outcomes in patients undergone all-arthroscopic autologous matrix induced chondrogenesis for symptomatic osteochondral talar lesions


Eligibility criteria:
inclusion criteria: * age over 18 years * males and females * patients underwent arthroscopic cartilage reconstruction surgery with amic technique for osteochondral lesions of the talus exclusion criteria: * age \<18 years at the time of surgery * patients with previous surgery on the affected ankle
multi-reader multi-case, retrospective study to evaluate effectiveness of cadai-b for breast

Conditions: Breast Cancer

Summary: the purpose of this study is to evaluate the effectiveness of lesion detection and diagnosis-aiding software (cadai-b for breast) during ultrasound (us) examination

cadai-b for breast is a real-time ai diagnosis system designed to assist healthcare professionals in lesion detection and differential diagnosis during breast us examinations. the primary objective of the study is to evaluate the effectiveness of cadai-b in the assistance of detection and diagnosis of breast cancer by comparing the clinical performance of physicians before and after using cadai-b in their ultrasound reading. the secondary objective of this study is to evaluate the sensitivity and specificity using cadai-b for us examinations.

Eligibility criteria:
inclusion criteria: * women who underwent breast us examination * women with breast cancer (dcis or invasive cancer) diagnosed via biopsy * women who had been followed for more than 2 years after initial us examination exclusion criteria: * women who had breast implants * women who had us images containing artifacts affecting the review of images
study of lenzilumab in previously treated patients with chronic myelomonocytic leukemia (cmml)

Conditions: Chronic Myelomonocytic Leukemia (CMML)

Summary: this is a multicenter, open-label, repeat-dose, phase 1 dose escalation study to evaluate safety, pharmacokinetics, and clinical activity.

the purpose of the study is to examine the safety and determine the recommended phase 2 dose of lenzilumab when administered to subjects with previously treated cmml who meet the entry criteria. study will begin enrollment in july 2016.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of cmml * cmml that is refractory to, or progressed following treatment with a hypomethylating agent or other standard of care treatment * eastern cooperative oncology group (ecog) score ≤ 2 * able to provide bone marrow biopsy samples * acceptable laboratory results exclusion criteria: * leukemia other than cmml * recent chemotherapy or radiation therapy (within 14 days before first dose of lenzilumab) * concurrent use of human granulocyte-macrophage colony-stimulating factor * pregnant or breastfeeding * know hiv virus infection * history of another malignancy within the past 2 years (some skin cancer and prostate cancers permitted) * significant intercurrent illness * history or current diagnosis of pulmonary alveolar proteinosis or hypoxemia

Keywords: cmml
a phase 2 study to determine the effects of bxt-51072 in diabetic patients undergoing angioplasty (pci)

Conditions: Acute Coronary Syndrome; Type 2 Diabetes

Summary: the purpose of this study is to determine the safety and feasibility of bxt-51072 as a cardioprotective agent in diabetics undergoing elective angioplasty / percutaneous intervention (pci), a procedure to "open" coronary arteries. bxt-51072 belongs to a class of drugs called "glutathione peroxidase mimics." bxt-51072 works by imitating a substance produced in various tissues in the body, which prevents damage of the heart and blood vessels.

following screening, baseline measurements and informed consent, patients will receive bxt-51072 40 mg or placebo in a 2:1 ratio, 30 minutes before their scheduled pci and then three times per day for 2 days. there will be 5 treatment visits and 3 follow-up visits. blood samples will be obtained for ck-mb, troponin and routine chemistry. a 24-hour continuous electrocardiogram will be obtained following the pci and regular electrocardiograms will be obtained during the study and follow-up period.

Eligibility criteria:
inclusion criteria: * type 2 diabetes * scheduled for elective angioplasty with acute coronary syndrome within 72- hours or mi within 7 days exclusion criteria: * ck-mb above normal * elevated troponin not showing a decreasing value * congestive heart failure * atrial fibrillation or left bundle branch block * uncontrolled diabetes
calcium and bone mass in young females

Conditions: Osteoporosis

Summary: we originally suggested that calcium in the diet is important in determining the amount of bone (bone mass) that builds up in young adults. we are testing the effect of calcium on bone mass in 354 caucasian (white) girls. at the start of this 7-year study, the average age of the girls was 11 years, and they had not yet reached puberty. the study will also provide information about the effect of calcium on body composition (body fat) and blood pressure in young women. we have been giving calcium to one group of participants in this study and giving a placebo (an inactive pill, or "sugar pill") to the other group. the results of this research will be important in preventing osteoporosis, because building more bone as a young person should reduce a woman's chances of developing osteoporosis later in life.

this study evaluates the effect of calcium on bone mass accretion over 7 years in a cohort of 354 young females who were in pubertal stage ii at the start of the study. the average age of study participants at entry was 11 years; at the end of the study participants were 18 years old. the study looks at skeletal development under the influence of heredity, nutrition (calcium), and physical exercise. we gave calcium to participants in one arm of this clinical trial calcium. participants in the other arm of the trial were given a placebo. the main outcome variable is the bone mass measured at different skeletal regions. the study will also provide data about the efficacy of calcium supplementation with regard to hypertension prevention and obesity. the results of this research will be important in preventing osteoporosis.

Eligibility criteria:
inclusion criteria: * pubertal stage ii * calcium intake below a threshold level * caucasian * normal health exclusion criteria: * medications affecting calcium and bone metabolism * chronic diseases * metabolic bone disease * abnormality in calcium metabolism

Keywords: osteoporosis dietary calcium puberty bone density bone mass primary prevention of osteoporosis
donor lymphocyte infusion after alternative donor transplantation

Conditions: Immunodeficiency

Summary: the purpose of this study is to determine the ability of a donor lymphocyte infusion (dli) given with methotrexate to hasten immune recovery without causing severe graft-versus-host disease (gvhd) in recipients who have had a t-cell depleted transplant.

studies have shown that giving donor t cells after a mismatched t cell-depleted stem cell transplant can speed up recovery of t cells in the patient. this approach can cause severe graft versus host disease (gvhd). the purpose of this study is to determine whether giving a donor lymphocyte infusion (dli) with methotrexate can accelerate immune recovery in recipients of t cell-depleted stem cell transplants. thirty days after a t-cell depleted transplant, patients will be given a dli. they will be monitored for immune recovery as measured by cd4 count and for gvhd toxicity. patients will be separated into six cohorts based on dose of dli received: 3 x 10\^4, 4 x 10\^4, 5 x 10\^4, 6 x 10\^4, 8 x 10\^4, and 10 x10\^4 cells/ kg of body weight. a minimum of 3 patients will be tested at each dose starting with the lowest dose. dose escalation will continue until the dose associated with cd4 count \>100 at day +120 after transplant without significant gvhd is determined. all patients will receive thirteen doses of methotrexate after the dli to prevent gvhd. patients will be followed for 2 years for outcomes.

Eligibility criteria:
inclusion criteria: * patients must have been treated on the lch bmt 09-01 protocol * signed informed consent by patient or legal guardian exclusion criteria: * active gvhd at the time when dli are due * history of acute gvhd \> grade i prior to dli * disease due to viral infection (eg. cmv) when dli are due (asymptomatic viral replication or viral shedding is not a contraindication) * uncontrolled bacterial or fungal infection * o2 saturation by pulse oximetry \< 95% * bilirubin \> 3mg/dl or alt \> 5 x upper limit of normal * creatinine \> 3x baseline (at transplant) * anc (wbc x % neutrophils + bands) \< 500/ul * significant effusions (eg. pleural or pericardial) or ascites * ebv-related ptld * persistent or increasing mixed chimerism requiring therapeutic dli as defined on the lch bmt 09-01 protocol

Keywords: donor lymphocyte infusion immune recovery t cell depleted transplant mismatched related donor transplants unrelated donor transplants
mental training for cfs following ebv infection in adolescents

Conditions: Fatigue Syndrome, Chronic; Epstein-Barr Virus Infection

Summary: the general aim of this study is to investigate the effect of an individually tailored mental training program in adolescents developing chronic fatigue syndrome (cfs) after an acute epstein barr-virus (ebv) infection. endpoints include physical activity (primary endpoint), symptoms (fatigue, pain, insomnia), cognitive function (executive functions) and markers of disease mechanisms (autonomic, endocrine, and immune responses).

ebv-infection is a well-known trigger of cfs. a closely related research project (chronic fatigue following acute epstein-barr virus infection in adolescents; clinicaltrials id:nct02335437) is a combined prospective and cross-sectional study of 200 adolescents suffering from acute ebv infection. the primary aim of that study is to identify factors that predispose to cfs 6 months after the acute infection. thus, that project will provide a sample of thoroughly characterized cfs patients, all having the same precipitation factor (ebv-infection). the present project is an intervention trial in the subgroup of patients that actually did develop cfs 6 months after the acute ebv infection. patients will be randomised 1:1 to either a mental training program (10 sessions) combining elements from cognitive behavioral therapy and music therapy, or routine follow-up from the general practitioner. by its nature, treatment group allocation cannot be blinded; however, both patients and therapists will be blinded for end-point evaluation. an extensive investigational program will be carried out at three time points: prior to the intervention, immediately after the intervention, and 1 year after the intervention. the program includes: clinical examination; pain threshold assessment; cardiovascular assessment; cognitive assessment; sampling of biological material (blood and urine); questionnaire; brain fmri; qualitative interview; monitoring of physical activity (accelerometer)

Eligibility criteria:
inclusion criteria: * participant in the research project ceba (chronic fatigue following acute epstein-barr virus infection in adolescents, nct02335437) * chronic fatigue at 6 months (a sum score of dichotomized responses ≥ 4 on the chalder fatigue questionnaire) exclusion criteria: * other illnesses that might explain the fatigue * bedridden